Ambulatory hypertensive patients treated by cardiologists in France

Jacques Blacher1, Julie Peroz-Froz, Jean-Pierre Huberman

  • 1Paris Descartes University, Faculté de Médecine, AP-HP, Diagnosis and Therapeutic Centre, Hôtel-Dieu, Paris, France. jacques.blacher@htd.aphp.fr

Insights

Hypertension control remains poor in France, with only 20.8% of patients treated by cardiologists achieving goal blood pressure (BP). Patient and physician factors significantly influence BP control, necessitating targeted strategies for improvement.

Area of Science:

  • Cardiology
  • Hypertension Management
  • Epidemiology

Background:

  • Hypertension is a leading cause of cardiovascular disease, with suboptimal control rates reported globally.
  • While general practitioners manage most hypertensive patients in France, cardiologists treat a high-risk population, necessitating a deeper understanding of their specific challenges.
  • Poor blood pressure (BP) control in hypertension persists, underscoring the need to identify influencing factors at both patient and physician levels.

Purpose of the Study:

  • To characterize the population of hypertensive patients managed by independent cardiologists in France.
  • To determine the prevalence of uncontrolled blood pressure (BP) in this population.
  • To identify patient- and physician-level factors associated with BP control.

Main Methods:

  • The COLHYGE study employed an observational, cross-sectional epidemiological design.
  • Data were collected from 5,798 consecutive patients treated by 371 independent cardiologists across France.
  • Patient and physician characteristics were assessed to analyze BP control determinants.

Main Results:

  • The study population exhibited high cardiovascular risk, with 27.5% in secondary prevention and 22.8% having diabetes.
  • Only 20.8% of patients achieved controlled BP.
  • Factors negatively associated with BP control included older age, higher BMI, increased heart rate, recent hypertension diagnosis, left ventricular hypertrophy, and patient perception of polypharmacy. Positive associations were observed with atrial fibrillation and the use of renin-angiotensin system blockers and fixed-dose combinations. Cardiologists in large cities and those in exclusive independent practices showed better BP control.

Conclusions:

  • The COLHYGE study confirms elevated cardiovascular risk and inadequate BP control in French patients managed by cardiologists.
  • Both patient-specific factors (e.g., comorbidities, medication beliefs) and physician-related aspects (e.g., practice setting) are critical determinants of BP control.
  • Future strategies to improve hypertension management should integrate considerations of both patient and physician characteristics.
Abstract

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
Hypertension V: Nursing Management01:23

Hypertension V: Nursing Management

The nursing management of hypertension involves accurately assessing symptoms, making a comprehensive nursing diagnosis, collaborating with patients to set goals, and implementing targeted interventions to mitigate the condition's impact and improve patient well-being.Comprehensive AssessmentThe initial step in nursing care for hypertension involves a thorough patient assessment. It includes evaluating symptoms such as headaches, dizziness, blurred vision, and previous hypertension episodes.
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...